Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

    Cancer Categories
    • Breast,Gastrointestinal (GI),Gynecologic,Head and Neck,Lung
    Karmanos Trial ID
    • 2023-007
    NCT ID
    • NCT04585750
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator


    Primary Objectives:

    • Determine the maximum tolerated dose (MTD), select a recommended Phase 2 dose (RP2D), and evaluate safety and tolerability of PC14586

    Secondary Objectives:

    • Characterize the pharmacokinetics (PK) of PC14586 when administered orally
    • Describe the concentrations of PC14586 and major metabolite (M1) when PC14586 is administered orally
    • Evaluate the preliminary efficacy of PC14586 using tumor response criteria
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266